DiaMedica Therapeutics
DMAC
28 hedge funds and large institutions have $7.42M invested in DiaMedica Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
207% more call options, than puts
Call options by funds: $175K | Put options by funds: $57K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.27% less ownership
Funds ownership: 15.16% → 13.88% (-1.3%)
18% less funds holding
Funds holding: 34 → 28 (-6)
26% less capital invested
Capital invested by funds: $10M → $7.42M (-$2.6M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$34.3K |
| 2 |
Morgan Stanley
New York
|
+$33.5K |
| 3 |
BlackRock
New York
|
+$24K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.05K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$553K |
| 2 |
Two Sigma Investments
New York
|
-$76.6K |
| 3 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$61.8K |
| 4 |
Two Sigma Advisers
New York
|
-$53K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$52K |
DMAC Hedge Fund Activity: Q2 2022 in Review
28 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2022, worth a combined $7.42M — down 26% from $10M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMAC and 1 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $34.3K. The largest seller was Ikarian Capital, exiting entirely with an estimated $553K sold.
- 28 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2022, down from 34 in Q1 2022.
- Funds reported $7.42M of DiaMedica Therapeutics stock for Q2 2022, down 26% quarter-over-quarter.
- 1 fund opened new DiaMedica Therapeutics positions in Q2 2022 and 7 closed out, a net change of -6 holders.
- The largest DiaMedica Therapeutics buyer in Q2 2022 was Cantor Fitzgerald, an estimated $34.3K added.
- The largest DiaMedica Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $553K sold.
Based on aggregated 13F filings for Q2 2022.